Rosenberg SA - Search Results

1

Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy.

Belldegrun A, Webb DE, Austin HA 3rd, Steinberg SM, Linehan WM, Rosenberg SA. Belldegrun A, et al. Among authors: rosenberg sa. J Urol. 1989 Mar;141(3):499-503. doi: 10.1016/s0022-5347(17)40872-x. J Urol. 1989. PMID: 2783983

2

Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.

Robertson CN, Linehan WM, Pass HI, Gomella LG, Haas GP, Berman A, Merino M, Rosenberg SA. Robertson CN, et al. Among authors: rosenberg sa. J Urol. 1990 Sep;144(3):614-7; discussion 617-8. doi: 10.1016/s0022-5347(17)39537-x. J Urol. 1990. PMID: 2201792 Clinical Trial.

3

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE. Rosenberg SA, et al. Ann Surg. 1989 Oct;210(4):474-84; discussion 484-5. doi: 10.1097/00000658-198910000-00008. Ann Surg. 1989. PMID: 2679456 Free PMC article.

4

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE. Rosenberg SA, et al. J Clin Oncol. 1989 Dec;7(12):1863-74. doi: 10.1200/JCO.1989.7.12.1863. J Clin Oncol. 1989. PMID: 2685181 Clinical Trial.

5

Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

Belldegrun A, Muul LM, Rosenberg SA. Belldegrun A, et al. Among authors: rosenberg sa. Cancer Res. 1988 Jan 1;48(1):206-14. Cancer Res. 1988. PMID: 3257161

6

Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer.

Belldegrun A, Uppenkamp I, Rosenberg SA. Belldegrun A, et al. Among authors: rosenberg sa. J Urol. 1988 Jan;139(1):150-5. doi: 10.1016/s0022-5347(17)42342-1. J Urol. 1988. PMID: 3257274

7

Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer.

Webb DE, Austin HA 3rd, Belldegrun A, Vaughan E, Linehan WM, Rosenberg SA. Webb DE, et al. Among authors: rosenberg sa. Clin Nephrol. 1988 Sep;30(3):141-5. Clin Nephrol. 1988. PMID: 3263237

8

Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer.

Belldegrun A, Webb DE, Austin HA 3rd, Steinberg SM, White DE, Linehan WM, Rosenberg SA. Belldegrun A, et al. Among authors: rosenberg sa. Ann Intern Med. 1987 Jun;106(6):817-22. doi: 10.7326/0003-4819-106-6-817. Ann Intern Med. 1987. PMID: 3495213

9

Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy.

Marcus SG, Choyke PL, Reiter R, Jaffe GS, Alexander RB, Linehan WM, Rosenberg SA, Walther MM. Marcus SG, et al. Among authors: rosenberg sa. J Urol. 1993 Aug;150(2 Pt 1):463-6. doi: 10.1016/s0022-5347(17)35514-3. J Urol. 1993. PMID: 8326579

10

Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma.

Walther MM, Alexander RB, Weiss GH, Venzon D, Berman A, Pass HI, Linehan WM, Rosenberg SA. Walther MM, et al. Among authors: rosenberg sa. Urology. 1993 Sep;42(3):250-7; discussion 257-8. doi: 10.1016/0090-4295(93)90612-e. Urology. 1993. PMID: 8379024

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,360 results

Search Page

Filters